Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Fig. 5

APG-115-enhanced antitumor activity in combination with anti-PD-1 blockade is abolished in Trp53 knockout mice implanted with Trp53mut MC38 tumor cells. The effect of APG-115 was evaluated in combination with anti-PD-1 antibody in a subcutaneous MC38 model established in Trp53 knockout C57BL/6 J mice (n = 12/group). APG-115 was orally administered every other day and anti-PD-1 antibody was administered intraperitoneally BIW

Back to article page